[144] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Amneal Pharmaceuticals (AMRX) submitted a Rule 144 notice reporting a proposed sale of 111,635 common shares with an aggregate market value of $1,006,947.00. The sale is planned on NASDAQ through Charles Schwab (3000 Schwab Way, Westlake, TX) with an approximate sale date of 08/13/2025. The filing shows 314,079,309 shares outstanding for the issuer.

The shares to be sold were acquired via RSU vesting on 03/01/2022 (23,916 shares) and 03/12/2022 (87,719 shares). The filer reports no securities sold in the past three months. The notice includes the standard representation that the filer does not possess undisclosed material adverse information and references trading-plan/Rule 10b5-1 considerations.

Insights

Securities Analyst

TL;DR Proposed sale is small relative to company size and is routine insider liquidity via vested RSUs.

The Rule 144 notice covers 111,635 shares valued at $1,006,947, to be executed on NASDAQ through Charles Schwab on 08/13/2025. Against the stated 314,079,309 shares outstanding, the position represents approximately 0.036% of the outstanding share count, indicating immaterial dilution or selling pressure. The shares were acquired through RSU vesting in March 2022 (23,916 and 87,719 shares). No sales were reported in the prior three months, and the filer affirms no undisclosed material adverse information. Overall, this looks like routine executive/insider liquidity rather than a material corporate development.

Corporate Governance Expert

TL;DR Disclosure follows standard Rule 144 practice; documentation of RSU origin and absence of recent sales reduces governance red flags.

The filing explicitly documents the origin of the shares (RSU vesting on 03/01/2022 and 03/12/2022) and confirms no securities sold in the past three months, which supports transparency around timing and intent. Use of a major broker (Charles Schwab) and the inclusion of the filer’s representation regarding material information and potential Rule 10b5-1 plans align with typical compliance expectations. From a governance perspective, this filing does not indicate unusual insider activity or disclosure gaps based on the provided facts.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab Corp. 3000 Schwab Way Westlake TX 76262	111635	1006947.00	314079309	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2022	RSU Vesting	Issuer			23916	03/01/2022	N/A
Common	03/12/2022	RSU Vesting	Issuer			87719	03/12/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Amneal (AMRX) file in this Rule 144 notice?

AMRX filed a Rule 144 notice reporting a proposed sale of 111,635 common shares with aggregate market value $1,006,947.00.

When and where is the proposed sale scheduled?

The approximate sale date is 08/13/2025, and the sale is planned on NASDAQ through broker Charles Schwab.

How were the shares being sold acquired?

The shares were acquired via RSU vesting: 03/01/2022 (23,916 shares) and 03/12/2022 (87,719 shares).

Has the filer sold any Amneal securities in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

How many shares outstanding does the filing report?

The filing lists 314,079,309 shares outstanding for the issuer.

Does the filer make any representation about material information or trading plans?

Yes, the filer represents they do not know of any undisclosed material adverse information and references trading-plan/Rule 10b5-1 considerations in the remarks.